Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength

vs
industry
vs
history
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth

vs
industry
vs
history
» DYAX's 10-Y Financials

Financials (Next Earnings Date: 0)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q4 2015

DYAX Guru Trades in Q4 2015

Mario Gabelli 187,150 sh (New)
Jeremy Grantham 546,377 sh (New)
Ken Fisher 185,375 sh (unchged)
Jim Simons Sold Out
Steven Cohen Sold Out
PRIMECAP Management 10,482,860 sh (-1.27%)
» More
Q1 2016

DYAX Guru Trades in Q1 2016

PRIMECAP Management 10,482,860 sh (unchged)
Jeremy Grantham Sold Out
Mario Gabelli Sold Out
Ken Fisher Sold Out
» More
Q2 2016

DYAX Guru Trades in Q2 2016

PRIMECAP Management 10,482,860 sh (unchged)
» More
Q3 2016

DYAX Guru Trades in Q3 2016

PRIMECAP Management 10,482,860 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with DYAX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Compare:NAS:UTHR, NAS:IONS, NAS:EXEL, NAS:JAZZ, NAS:ALNY, NAS:TECH, NAS:TSRO, NYSE:XON, NAS:RARE, NAS:ACAD, NAS:CBPO, NAS:ICPT, OTCPK:BTGGF, NAS:GLPG, NAS:KITE, NAS:JUNO, NAS:BLUE, NAS:ALKS, NAS:LGND, NAS:PRTA » details
Traded in other countries:DY8.Germany,


Dyax Corp was incorporated in the state of Delaware in the year 1989, and merged with Protein Engineering Corporation in 1995. It is a biopharmaceutical company focused on Hereditary Angioedema and Other Plasma-Kallikrein-Mediated Disorders and Licensing and Funded Research Portfolio. The Company develops and commercializes treatments for hereditary angioedema and to identify other disorders that are mediated by plasma kallikrein. It is engaged in identifying and developing treatments for patients who experience PKM angioedema. Plasma kallikrein, an enzyme found in blood, produces bradykinin, a protein that causes blood vessels to enlarge or dilate, which can cause swelling known as angioedema. Excess plasma kallikrein activity plays a role in HAE and could potentially play a role in a number of inflammatory diseases, including Crohn's disease, psoriasis, rheumatoid arthritis, and various mast cell disorders. It also develops KALBITOR for the treatment of acute attacks of HAE. KALBITOR is currently distributed through a limited network of wholesale, hospital and specialty pharmacy arrangements. Its portfolio of product candidates being developed by licensees using its phage display technology. For KALBITOR as a treatment for HAE, its competitors include: Manufacturers of corticosteroids. Other competitors for the treatment of HAE are companies that are developing small molecule plasma kallikrein inhibitors. The preclinical study and clinical testing, manufacture, labeling, storage, record keeping, advertising, promotion, export, and marketing, among other things, of its products and product candidates, including KALBITOR and those of its licensees, are subject to extensive regulation by governmental authorities in the United States and other countries.

Guru Investment Theses on Dyax Corp

Mario Gabelli Comments on Dyax Corp - May 03, 2016

Dyax Corp. (NASDAQ:DYAX) is a Burlington, Massachusetts based biopharmaceutical company. The company is targeting hereditary angioedema (HAE), a rare, genetic inflammatory condition, via their pipeline drug DX-2930, an injectable treatment for the treatment of acute HAE. On November 2, 2015, the company received a $5.9 billion cash merger offer by Shire plc, a leading specialty pharmaceutical company with an interest in the HAE space. The offer was structured to include $37.30 cash per share at closing, along with a contingent value right (CVR) (0.1% of net assets as of March 31, 2016) potentially worth $4.00. The CVR is tied to the FDA approving DX-2930 by 2019. The deal was approved by U.S. antitrust regulators, and it closed on January 22, 2016. No return data is available for the deal at this time because of the CVR structure and unknown future payout amounts.



From Mario Gabelli (Trades, Portfolio)'s first quarter 2016 ABC Fund shareholder commentary.

Check out Mario Gabelli latest stock trades

Meridian Funds Comments on Dyax Corp - Mar 07, 2016

Dyax Corp. (NASDAQ:DYAX) is a biopharmaceutical company focused on novel therapeutics for patients with rare diseases. One of the things that initially attracted us to this company was its development of a promising new drug for hereditary angioedema, a rare and potentially life-threatening disease that causes swelling. Ireland-based biopharmaceutical company Shire also recognized the potential of this experimental drug and, in November, offered to purchase Dyax in an all-cash deal valued at approximately $5.9 billion—a premium of about 35%. We were pleased to be among the investors who benefited from this lucrative deal.



From Meridian Growth Fund Semi-Annual Letter to Shareholders 2016.



Check out Meridian Funds latest stock trades

Mario Gabelli Comments on Dyax Corp - Jan 29, 2016

Dyax Corp. (2.2%) (DYAX – $37.62 – NASDAQ) (NASDAQ:DYAX) is a Burlington, Massachusetts based biopharmaceutical company. The company is targeting hereditary angioedema (HAE), a rare, genetic inflammatory condition, via their pipeline drug DX-2930, an injectable treatment for acute HAE. On November 2, 2015, the company received a $5.9 billion cash merger offer by Shire plc, a leading specialty pharmaceutical company with an interest in the HAE space. The offer is structured to include $37.30 cash per share at closing, along with a contingent value right (CVR) potentially worth $4.00. The CVR is tied to the FDA approving DX-2930 by 2019. The deal closed on January 22, 2016.


From Mario Gabelli (Trades, Portfolio)'s ABC Fund Merger and Arbitrage shareholder letter for the fourth quarter 2015.

Check out Mario Gabelli latest stock trades

Top Ranked Articles about Dyax Corp

Mario Gabelli Comments on Dyax Corp Guru stock highlight
Dyax Corp. (NASDAQ:DYAX) is a Burlington, Massachusetts based biopharmaceutical company. The company is targeting hereditary angioedema (HAE), a rare, genetic inflammatory condition, via their pipeline drug DX-2930, an injectable treatment for the treatment of acute HAE. On November 2, 2015, the company received a $5.9 billion cash merger offer by Shire plc, a leading specialty pharmaceutical company with an interest in the HAE space. The offer was structured to include $37.30 cash per share at closing, along with a contingent value right (CVR) (0.1% of net assets as of March 31, 2016) potentially worth $4.00. The CVR is tied to the FDA approving DX-2930 by 2019. The deal was approved by U.S. antitrust regulators, and it closed on January 22, 2016. No return data is available for the deal at this time because of the CVR structure and unknown future payout amounts. Read more...
Meridian Funds Comments on Dyax Corp Guru stock highlight
Dyax Corp. (NASDAQ:DYAX) is a biopharmaceutical company focused on novel therapeutics for patients with rare diseases. One of the things that initially attracted us to this company was its development of a promising new drug for hereditary angioedema, a rare and potentially life-threatening disease that causes swelling. Ireland-based biopharmaceutical company Shire also recognized the potential of this experimental drug and, in November, offered to purchase Dyax in an all-cash deal valued at approximately $5.9 billion—a premium of about 35%. We were pleased to be among the investors who benefited from this lucrative deal. Read more...
Mario Gabelli Comments on Dyax Corp Guru stock highlight
Dyax Corp. (2.2%) (DYAX – $37.62 – NASDAQ) (NASDAQ:DYAX) is a Burlington, Massachusetts based biopharmaceutical company. The company is targeting hereditary angioedema (HAE), a rare, genetic inflammatory condition, via their pipeline drug DX-2930, an injectable treatment for acute HAE. On November 2, 2015, the company received a $5.9 billion cash merger offer by Shire plc, a leading specialty pharmaceutical company with an interest in the HAE space. The offer is structured to include $37.30 cash per share at closing, along with a contingent value right (CVR) potentially worth $4.00. The CVR is tied to the FDA approving DX-2930 by 2019. The deal closed on January 22, 2016.
Read more...

Ratios

vs
industry
vs
history

Buy Back

vs
industry
vs
history

Valuation & Return

vs
industry
vs
history

More Statistics

Revenue (TTM) (Mil) $97.55
EPS (TTM) $ -0.21
Short Percentage of Float2.93%
52-Week Range $14.06 - 38.56
Shares Outstanding (Mil)147.18

Analyst Estimate

Dec15 Dec16 Dec17 Dec18
Revenue (Mil $) 98 116 115 372
EPS ($) -0.26 -0.20 -0.23 1.05
EPS w/o NRI ($) -0.26 -0.20 -0.23 1.05
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)
» More Articles for DYAX

Headlines

Articles On GuruFocus.com
Mario Gabelli Comments on Dyax Corp May 03 2016 
The Gabelli ABC Fund 1st Quarter Shareholder Commentary May 03 2016 
Meridian Funds Comments on Dyax Corp Mar 07 2016 
Meridian Growth Fund Semi-Annual Letter to Shareholders Mar 07 2016 
Mario Gabelli Comments on Dyax Corp Jan 29 2016 
Chuck Royce Makes Big Gains on Divestitures Jan 03 2016 
Voltari Corp. (VLTC) Under Carl Icahn Umbrella, Dyax Corp. (DYAX) Potential Angioedema Preventive Tr Apr 01 2015 
Weekly CFO Buys Highlight: DYAX, IBI, FARM, TAP, DBM Mar 19 2011 
Dyax Corp. (DYAX) CEO Gustav Christensen buys 10,000 Shares Mar 15 2011 
Dyax Corp. (DYAX) CEO Gustav Christensen buys 10,000 Shares Mar 15 2011 

More From Other Websites
Peter Kolchinsky Is Betting Big On Achillion Pharmaceuticals, Inc. (ACHN), Wave Life Sciences (WVE)... Feb 25 2016
Here Are The Most Notable Insider Transactions Hitting The Market Jan 26 2016
DYAX CORP Files SEC form 8-K, Completion of Acquisition or Disposition of Assets, Notice of... Jan 22 2016
Shire Completes Acquisition of Dyax Jan 22 2016
Technical Scrutiny on Biotechnology Stocks -- Gilead Sciences, Sarepta Therapeutics, Dyax Corp., and... Jan 21 2016
3 Stocks Making New 52-Week Highs Jan 20 2016
The Zacks Analyst Blog Highlights: ALPS Medical Breakthroughs ETF, Anacor Pharmaceuticals, Dyax,... Dec 29 2015
5 Top Performing Stocks of the Top ETF of 2015 Dec 28 2015
DYAX CORP Files SEC form 8-K, Other Events, Financial Statements and Exhibits Dec 11 2015
Dyax Corp. Sets January 21, 2016 As Date of Special Stockholder Meeting To Vote On Its Proposed... Dec 11 2015
DYAX CORP Financials Dec 08 2015
Dyax Corp. Presents DX-4012 Data at the 2015 American Society of Hematology Annual Meeting Dec 06 2015
The SPDR S&P Biotech ETF Lingers in the Red as of December 3 Dec 04 2015
Strength Seen in Dyax Corp (DYAX): Stock Rises 12.2% Dec 04 2015
DYAX CORP Files SEC form 8-K, Other Events, Financial Statements and Exhibits Dec 02 2015
Do Hedge Funds Love Dyax Corp. (DYAX)? Dec 01 2015
Is Vista Outdoor Inc (VSTO) A Good Stock To Buy? Nov 24 2015
5 BioPharma Movers That Cannot Be Ignored Nov 07 2015
DYAX CORP Files SEC form 10-Q, Quarterly Report Nov 06 2015
DYAX CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Amendments to Articles of... Nov 02 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)